Low level TGF-β1-treated Umbilical mesenchymal stem cells attenuates microgliosis and neuropathic pain in chronic constriction injury by exosomes/lncRNA UCA1／miR-96-5p／FOXO3a.
Exosomes
FOXO3a
Mesenchymal stem cells
Microgliosis
Neuropathic pain
TGF-β1
lncRNA UCA1
Journal
Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
09
01
2023
revised:
19
04
2023
accepted:
21
04
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Neuropathic pain is a chronic pain state that usually caused by injuries in peripheral or central nerve. Inhibition of spinal microglial response is a promising treatment of neuropathic pain caused by peripheral nerve injury. In recent years, mesenchymal stem cells (MSCs) that characterized with multipotent ability have been widely studied for disease treatment. TGF-β1 is a well-known regulatory cytokine that participate in the response to cell stress and is closely correlated with the function of nerve system as well as MSC differentiation. This work aimed to determine the effects of exosomes that extracted from TGF-β1-induced umbilical mesenchymal stem cells (hUCSMCs) on the neuropathic pain. In this work, we established a rat model of chronic constriction injury (CCI) of the sciatic nerve and LPS-induced microglia cell model. The hUCSMCs cell surface biomarker was identified by flow cytometry. Exosomes that extracted from TGF-β1-treated hUCSMCs were characterized by transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA) and used for treatment. We observed that TGF-β1 upregulates the level of lncRNA UCA1 (UCA1) in hUCMSC-derived exosomes. Treatment with exosomal lncRNA UCA1 (UCA1) alleviated the neuropathic pain, microgliosis, and production of inflammatory mediator both in vivo and in vitro. UCA1 directly interact with the miR-96-5p, and the miR-96-5p acts as sponge of FOXO3a. Knockdown of UCA1 upregulated the level of miR-96-5p and downregulated the FOXO3a expression, which could be recovered by inhibition of miR-96-5p. In summary, the TGF-β1-stimulated exosomal UCA1 from hUCMSCs alleviates the neuropathic pain and microgliosis. These findings may provide novel evidence for treatment of neuropathic pain caused by chronic constriction injury.
Identifiants
pubmed: 37153860
doi: 10.1016/j.bbrep.2023.101477
pii: S2405-5808(23)00058-4
pmc: PMC10160346
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101477Informations de copyright
© 2023 Everunion Biotechnology Co. LTD., Tianjin. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Stem Cell Res Ther. 2021 Aug 3;12(1):434
pubmed: 34344478
Nat Rev Neurosci. 2018 Mar;19(3):138-152
pubmed: 29416128
Tissue Eng Part A. 2022 Jul;28(13-14):651-659
pubmed: 35019728
Oxid Med Cell Longev. 2021 Nov 02;2021:6219715
pubmed: 34765084
J Transl Med. 2021 May 30;19(1):229
pubmed: 34053467
Pain. 2018 Mar;159(3):595-602
pubmed: 29447138
Int Arch Allergy Immunol. 2021;182(3):210-219
pubmed: 33477144
Cancer Commun (Lond). 2021 Feb;41(2):109-120
pubmed: 33119215
Science. 2022 Apr;376(6588):86-90
pubmed: 35357926
Cell Tissue Res. 2021 Apr;384(1):113-127
pubmed: 33404840
Semin Neurol. 2018 Dec;38(6):644-653
pubmed: 30522140
Physiol Rev. 2021 Jan 1;101(1):259-301
pubmed: 32584191
Microsc Microanal. 2021 Apr;27(2):450-456
pubmed: 33588960
Int Immunopharmacol. 2019 Oct;75:105734
pubmed: 31301558
Rev Neurol (Paris). 2019 Jan - Feb;175(1-2):16-25
pubmed: 30385075
Pain. 2019 Jan;160(1):210-223
pubmed: 30188455
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:257-274
pubmed: 31914896
Mol Carcinog. 2020 Oct;59(10):1174-1187
pubmed: 32805084
Br J Anaesth. 2017 Apr 1;118(4):504-516
pubmed: 28403399
J Neuroinflammation. 2020 May 11;17(1):154
pubmed: 32393298
Stem Cells Int. 2021 Jul 9;2021:9964877
pubmed: 34306098
J Clin Lab Anal. 2021 Mar;35(3):e23697
pubmed: 33458871
Elife. 2020 Oct 23;9:
pubmed: 33095159
Mayo Clin Proc. 2015 Apr;90(4):532-45
pubmed: 25841257
Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):12859-12866
pubmed: 33378036
Stem Cells Dev. 2020 Nov 15;29(22):1420-1428
pubmed: 32962522
Neuropeptides. 2019 Jun;75:75-84
pubmed: 31030907
Stem Cell Res Ther. 2020 Jan 29;11(1):41
pubmed: 31996252
Cell Tissue Res. 2018 Oct;374(1):99-110
pubmed: 29858667
Int Immunopharmacol. 2019 Feb;67:268-280
pubmed: 30572251
Neurochem Res. 2020 Apr;45(4):783-795
pubmed: 32056051
IUBMB Life. 2021 Feb;73(2):463-473
pubmed: 33368965
Pain. 1988 Apr;33(1):87-107
pubmed: 2837713
Int J Cancer. 2017 Jan 15;140(2):411-422
pubmed: 27716965
J Neurol. 2018 Feb;265(2):231-238
pubmed: 29032407
Biochem Pharmacol. 2019 Nov;169:113614
pubmed: 31445020
Adv Exp Med Biol. 2018;1099:77-91
pubmed: 30306516
Carcinogenesis. 2022 May 19;43(4):371-381
pubmed: 35018436
J Gene Med. 2020 Aug;22(8):e3188
pubmed: 32196830
Nat Rev Mol Cell Biol. 2022 Jun;23(6):389-406
pubmed: 35079163
Life Sci. 2021 Jul 15;277:119569
pubmed: 33961855
Front Oncol. 2021 Nov 19;11:671082
pubmed: 34868904